Krystal Biotech (NASDAQ:KRYS) Stock Price Target Cut by Royal Bank Of Canada

Krystal Biotech (NASDAQ:KRYS) had its price objective decreased by equities researchers at Royal Bank Of Canada from $400.00 to $375.00 in a report released on Tuesday, Benzinga reports. The firm currently has an “outperform” rating on the stock. Royal Bank Of Canada‘s target price points to a potential upside of 24.52% from the stock’s previous close.

A number of other brokerages have also commented on KRYS. William Blair upgraded shares of Krystal Biotech to a “strong-buy” rating in a report on Wednesday, September 23rd. The Goldman Sachs Group assumed coverage on shares of Krystal Biotech in a research report on Thursday, September 24th. They issued a “buy” rating and a $441.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $361.00 target price on shares of Krystal Biotech in a research note on Thursday, October 15th. Bank of America increased their target price on Krystal Biotech from $392.00 to $400.00 and gave the stock a “buy” rating in a report on Monday, September 21st. Finally, Jefferies Financial Group reissued a “buy” rating and issued a $474.00 price target on shares of Krystal Biotech in a research note on Monday, July 13th. Two research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $374.70.

Krystal Biotech Stock Performance

KRYS stock traded up $5.26 during mid-day trading on Tuesday, hitting $301.16. 41,546 shares of the company were exchanged, compared to its average volume of 327,187. The firm has a market cap of $8.91 billion, a P/E ratio of 37.84 and a beta of 0.50. The firm’s 50 day simple moving average is $336.45 and its 200 day simple moving average is $308.70. Krystal Biotech has a 1-year low of $192.52 and a 1-year high of $382.54.

Krystal Biotech (NASDAQ:KRYS) last announced its quarterly earnings results on Monday, November 2nd. The company reported $2.05 earnings per share for the quarter, beating analysts’ consensus estimates of $1.79 by $0.26. The firm had revenue of $127.34 million for the quarter, compared to analyst estimates of $125.77 million. Krystal Biotech had a net margin of 54.82% and a return on equity of 19.34%. On average, equities research analysts predict that Krystal Biotech will post 7.33 EPS for the current fiscal year.

Insider Activity at Krystal Biotech

In other news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Friday, September 4th. The shares were sold at an average price of $359.32, for a total transaction of $8,983,000.00. Following the completion of the transaction, the insider directly owned 1,302,145 shares of the company’s stock, valued at $467,886,741.40. This trade represents a 1.88% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Dino Rossi sold 25,000 shares of Krystal Biotech stock in a transaction that occurred on Friday, August 14th. The shares were sold at an average price of $329.12, for a total transaction of $8,228,000.00. Following the completion of the sale, the director owned 50,000 shares in the company, valued at $16,456,000. This trade represents a 33.33% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. 13.10% of the stock is owned by company insiders.

Institutional Investors Weigh In On Krystal Biotech

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Signaturefd LLC lifted its position in Krystal Biotech by 27.3% during the 3rd quarter. Signaturefd LLC now owns 168 shares of the company’s stock worth $56,000 after buying an additional 36 shares in the last quarter. Torray Investment Partners LLC grew its holdings in shares of Krystal Biotech by 0.4% in the 1st quarter. Torray Investment Partners LLC now owns 12,032 shares of the company’s stock valued at $3,108,000 after acquiring an additional 47 shares in the last quarter. Oregon Public Employees Retirement Fund increased its position in shares of Krystal Biotech by 0.9% in the first quarter. Oregon Public Employees Retirement Fund now owns 5,949 shares of the company’s stock valued at $1,537,000 after acquiring an additional 53 shares during the last quarter. Hanseatic Management Services Inc. increased its position in shares of Krystal Biotech by 2.0% in the third quarter. Hanseatic Management Services Inc. now owns 3,183 shares of the company’s stock valued at $1,059,000 after acquiring an additional 63 shares during the last quarter. Finally, Heritage Family Offices LLP bought a new stake in Krystal Biotech during the third quarter worth about $25,000. 86.29% of the stock is currently owned by institutional investors and hedge funds.

Trending Headlines about Krystal Biotech

Here are the key news stories impacting Krystal Biotech this week:

• Positive Sentiment: Krystal reported third-quarter EPS of $2.05, exceeding consensus estimates ranging from $1.79 to $1.92, while revenue of $127.34 million also topped expectations. The results were supported by continued demand for Vyjuvek. Earnings Beat May Change The Case For Krystal Biotech Stock
• Positive Sentiment: Management authorized a $400 million share-repurchase program over two years. Buybacks could support earnings per share and provide near-term demand for the stock. Krystal Biotech’s $400 Million Buyback
• Positive Sentiment: Analysts and market commentary highlighted Vyjuvek’s commercial strength, revenue growth and the possibility that the earnings beat could improve the investment outlook. Krystal Biotech Beats on Vyjuvek Strength
• Neutral Sentiment: Krystal revised its 2026 non-GAAP operating-expense outlook to $155 million–$165 million, reflecting continued investment in its clinical portfolio. Krystal Outlines $400 Million Share Repurchase
• Negative Sentiment: Third-quarter profit declined from the prior year despite the earnings beat, raising concerns about growth quality and the sustainability of profitability. Krystal’s Q3 Profit Declines
• Negative Sentiment: Timelines for parts of Krystal’s development pipeline slipped into 2027, delaying potential catalysts and contributing to investor disappointment. The buyback also creates an opportunity-cost and funding-risk debate while the company continues investing in clinical programs. Krystal Biotech Stock Stays Above Fair Value After Buyback Plan
• Negative Sentiment: With KRYS trading above some estimates of fair value and below its recent highs, investors appear to be demanding stronger forward growth to justify the valuation. Is Krystal Biotech Undervalued?

About Krystal Biotech

Krystal Biotech, Inc is a biotechnology company focused on developing and commercializing genetic medicines for rare diseases. The company’s platform uses modified herpes simplex virus type 1 vectors to deliver functional genes to target tissues, with an emphasis on therapies that can be administered repeatedly.

Krystal’s lead product, VYJUVEK, is a topical gene therapy for wounds associated with dystrophic epidermolysis bullosa, a rare inherited skin disorder caused by mutations affecting type VII collagen.